AR087508A1 - 3,4-dihidro-1h-[1,8]naftiridinonas antibacterianas sustituidas con ciclopenta[c]pirrol - Google Patents

3,4-dihidro-1h-[1,8]naftiridinonas antibacterianas sustituidas con ciclopenta[c]pirrol

Info

Publication number
AR087508A1
AR087508A1 ARP120102929A ARP120102929A AR087508A1 AR 087508 A1 AR087508 A1 AR 087508A1 AR P120102929 A ARP120102929 A AR P120102929A AR P120102929 A ARP120102929 A AR P120102929A AR 087508 A1 AR087508 A1 AR 087508A1
Authority
AR
Argentina
Prior art keywords
benzyl
alkyl
halo
heteroaryl
hydrogen
Prior art date
Application number
ARP120102929A
Other languages
English (en)
Spanish (es)
Original Assignee
Janssen R & D Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46650549&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR087508(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen R & D Ireland filed Critical Janssen R & D Ireland
Publication of AR087508A1 publication Critical patent/AR087508A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP120102929A 2011-08-10 2012-08-10 3,4-dihidro-1h-[1,8]naftiridinonas antibacterianas sustituidas con ciclopenta[c]pirrol AR087508A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11177119 2011-08-10

Publications (1)

Publication Number Publication Date
AR087508A1 true AR087508A1 (es) 2014-03-26

Family

ID=46650549

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102929A AR087508A1 (es) 2011-08-10 2012-08-10 3,4-dihidro-1h-[1,8]naftiridinonas antibacterianas sustituidas con ciclopenta[c]pirrol

Country Status (24)

Country Link
US (7) US8906923B2 (enExample)
EP (1) EP2742045B1 (enExample)
JP (2) JP5921687B2 (enExample)
KR (1) KR101996862B1 (enExample)
CN (2) CN105461684B (enExample)
AR (1) AR087508A1 (enExample)
AU (1) AU2012293621B2 (enExample)
BR (1) BR112014003063B1 (enExample)
CA (1) CA2842518C (enExample)
CL (1) CL2014000289A1 (enExample)
DK (1) DK2742045T3 (enExample)
EA (1) EA201490438A1 (enExample)
ES (1) ES2721658T3 (enExample)
HU (1) HUE042978T2 (enExample)
IL (1) IL230549A (enExample)
JO (1) JO3611B1 (enExample)
MX (1) MX348128B (enExample)
PE (1) PE20141410A1 (enExample)
PH (1) PH12014500317A1 (enExample)
TR (1) TR201905537T4 (enExample)
TW (1) TWI568731B (enExample)
UA (1) UA111210C2 (enExample)
UY (1) UY34253A (enExample)
WO (1) WO2013021054A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3611B1 (ar) * 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
EP2742047B1 (en) 2011-08-10 2021-05-12 Janssen Sciences Ireland Unlimited Company Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones
US9315522B2 (en) * 2012-08-10 2016-04-19 Janssen Sciences Ireland Uc Antibacterial compounds
EP3461827B1 (en) 2013-09-26 2022-02-23 Cadent Therapeutics, Inc. Selective octahydro-cyclopenta[c]pyrrole negative modulators of nr2b
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
EP3680241A1 (en) 2017-03-20 2020-07-15 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
US11691967B2 (en) 2018-03-12 2023-07-04 The Board Of Trustees Of The University Of Illinois Antibiotics effective for gram-negative pathogens
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R
FI3880675T3 (fi) 2018-11-12 2024-12-09 Debiopharm Int Sa Antibioottiyhdisteitä, menetelmiä niiden valmistamiseksi, niitä sisältäviä farmaseuttisia koostumuksia ja niiden käyttöjä
HUE072832T2 (hu) 2019-09-19 2025-12-28 Novo Nordisk Healthcare Ag Piruvát kináz R-t (PKR) aktiváló készítmények
CA3212074A1 (en) * 2021-03-17 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215123A (en) * 1979-05-07 1980-07-29 American Home Products Corporation Antisecretory 4-oxy-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
AR025976A1 (es) 1999-10-08 2002-12-26 Affinium Pharm Inc Inhibidores de fab i.
WO2001026654A1 (en) 1999-10-08 2001-04-19 Smithkline Beecham Corporation Fab i inhibitors
EP1225894B1 (en) 1999-10-08 2006-07-05 Affinium Pharmaceuticals, Inc. Fab i inhibitors
CA2444597A1 (en) 2001-04-06 2002-10-06 Affinium Pharmaceuticals, Inc. Fab i inhibitors
CA2568914C (en) * 2004-06-04 2013-09-24 Affinium Pharmaceuticals, Inc. Therapeutic agents, and methods of making and using the same
US7732612B2 (en) 2004-09-09 2010-06-08 Janssen Pharmaceutica, N.V. 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones
US7973060B2 (en) 2005-10-13 2011-07-05 Crystalgenomics, Inc. Fab I inhibitor and process for preparing same
EP2687533B1 (en) * 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
JP5816629B2 (ja) 2009-11-18 2015-11-18 ファブ ファーマ エスエーエス 新規の複素環式アクリルアミド及び医薬としてのその使用
JP2014524409A (ja) 2011-07-29 2014-09-22 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア Hivの治療のための組成物および方法
US8766017B2 (en) 2011-07-29 2014-07-01 Eastman Chemical Company Integrated process for the preparation of 1,4-cyclohexanedimethanol from terephthalic acid
EP2742047B1 (en) 2011-08-10 2021-05-12 Janssen Sciences Ireland Unlimited Company Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones
KR101996866B1 (ko) 2011-08-10 2019-07-05 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항균성 호모피페리디닐 치환 3,4-디하이드로-1h-[1,8]나프티리디논
JO3611B1 (ar) * 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم

Also Published As

Publication number Publication date
US8906923B2 (en) 2014-12-09
US9290493B2 (en) 2016-03-22
CN103874698A (zh) 2014-06-18
NZ620212A (en) 2015-10-30
HK1223352A1 (zh) 2017-07-28
US10526331B2 (en) 2020-01-07
PE20141410A1 (es) 2014-10-13
EA201490438A1 (ru) 2014-06-30
DK2742045T3 (en) 2019-04-23
TWI568731B (zh) 2017-02-01
CN105461684B (zh) 2018-09-25
JO3611B1 (ar) 2020-08-27
CN105461684A (zh) 2016-04-06
ES2721658T3 (es) 2019-08-02
KR101996862B1 (ko) 2019-07-05
US20140171451A1 (en) 2014-06-19
US9617262B2 (en) 2017-04-11
CA2842518C (en) 2019-07-23
AU2012293621B2 (en) 2016-07-21
PH12014500317A1 (en) 2014-04-14
JP2014531404A (ja) 2014-11-27
US20180105525A1 (en) 2018-04-19
UA111210C2 (uk) 2016-04-11
WO2013021054A1 (en) 2013-02-14
CL2014000289A1 (es) 2014-07-11
US10155759B2 (en) 2018-12-18
BR112014003063A2 (pt) 2017-02-21
UY34253A (es) 2013-02-28
CA2842518A1 (en) 2013-02-14
TR201905537T4 (tr) 2019-05-21
US20190084982A1 (en) 2019-03-21
US20170174683A1 (en) 2017-06-22
BR112014003063B1 (pt) 2020-11-17
EP2742045A1 (en) 2014-06-18
JP5921687B2 (ja) 2016-05-24
KR20140072034A (ko) 2014-06-12
JP2016190843A (ja) 2016-11-10
HK1199243A1 (zh) 2015-06-26
MX2014001600A (es) 2014-04-25
US20190194194A1 (en) 2019-06-27
HUE042978T2 (hu) 2019-07-29
IL230549A (en) 2017-07-31
US9884864B2 (en) 2018-02-06
CN103874698B (zh) 2016-03-23
EP2742045B1 (en) 2019-01-23
AU2012293621A1 (en) 2014-02-13
US20160194324A1 (en) 2016-07-07
US20150080413A1 (en) 2015-03-19
TW201313714A (zh) 2013-04-01
MX348128B (es) 2017-05-26
US10501463B2 (en) 2019-12-10
IL230549A0 (en) 2014-03-31

Similar Documents

Publication Publication Date Title
ES2721658T3 (es) 3,4-dihidro-1h-[1,8]naftiridinonas sustituidas con ciclopenta[c]pirrol antibacterianas
ES2653265T3 (es) Morfinanos sustituidos y el uso de éstos
ECSP11011365A (es) Sales de adición de aminas que contienen grupos hidroxilo y/o carboxílicos con derivados de ácido aminonicotínico como inhibidores de dhodh
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
PH12015501083B1 (en) Novel pyridine derivatives
MX2015007883A (es) Compuestos para protección de células.
MY153617A (en) Pyridin-4-yl derivatives
CA2875877C (en) Syk inhibitors
AR092790A1 (es) Derivados bencimidazolicos del acido hidroxamico
AR073598A1 (es) Pirrolidinas 2-carboxamidas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas como agentes anticancer.
CO6241157A2 (es) "derivados de 6-(pirrolidin-3-il)-1h-pirazolo{3,4-d}pirimidin-4(5h)-ona utiles como inhibidores de pde9"
AR094911A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃
AR087919A1 (es) Heterociclos biciclicos como inhibidores de irak4
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
MX343264B (es) Ciertas amino-piridazinas, composiciones de las mismas y metodos de uso de los mismos.
PH12015501843A1 (en) Novel pyrazol derivatives
AR091271A1 (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa
PH12015501073A1 (en) Novel pyridine derivatives
NZ709986A (en) Pharmaceutical compositions comprising nitroxyl donors
AR066153A1 (es) Derivados de piperidina / piperazina
PH12015501933A1 (en) Novel pyridine derivatives
MY169179A (en) Novel piperidine compound or salt thereof
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
ES2570167T3 (es) Derivados de benzimidazol como inhibidores de glutaminil ciclasa

Legal Events

Date Code Title Description
FG Grant, registration